AzTrials
AzTrials

To Determine If Blood Level (NGAL) Could Accurately Early Detect Acute Renal Damage in All Patients Requiring Critical CareNGAL AKINCT06691607

NGAL in Prediction of AKI and Patient Outcomes

An observational study of To Determine If Blood Level (NGAL) Could Accurately Early Detect Acute Renal Damage in All Patients Requiring Critical Care, run by Sohag University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This single-center prospective non-randomized observational research included 120 critically ill persons, at Sohag University hospital's critical care unit. NGAL serum level was assessed at admission to the intensive care unit (NGAL1) and 24 hours after first sample (NGAL2). Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Serum NGAL level
How many people
120 participants
Where
1 siteEgypt
Study dates
1 Apr 2020to 1 Jun 2022
How long will I take part?
7 Days
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All included patients were subjected to the following: History taking, demographic data, full medical history before ICU admission. Complete clinical examination immediately on admission. NGAL was measured by (ELISA) at admission and after 24 hours. Serum level of creatinine was measured immediately on admission and every 24 hours. Routine Laboratory investigations, abdominal ultrasound comment on kidney echogenicity was performed. Utilizing the RIFLE-SCr method, participants were split into two groups: group A that advanced acute kidney injury or failure during their intensive care unit stay, and group B that didn't. Patients with AKI should consider dialysis if they have been indicated.

Who may be able to join

  • All severely sick ICU patients older than 18 years old were included in the study

Who cannot join

  • Patients with known chronic renal disease, those receiving hemodialysis, those with transplanted kidney, those with known kidney cancer, and patients who were just released from the ICU

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Sohag University

    Sohag, Sohag Governorate

Other trials in Egypt

About this study

Official title: The Role of Neutrophil Gelatinase Associated Lipocalin in Early Detection of Acute Kidney Injury and Prediction of Patient Outcome in Critically Ill Patients; a Prospective, Observational, Non-randomized Study

This single-center prospective non-randomized observational research included 120 critically ill persons, at Sohag University hospital's critical care unit. NGAL serum level was assessed at admission to the intensive care unit (NGAL1) and 24 hours after first sample (NGAL2). Cases were categorized into two groups depending on their progression or not to AKI, group A or group B respectively during their intensive care unit stay. Serum NGAL1 and NGAL2 concentrations were compared in relation to development of AKI (group A) or not (group B), need for RRT or not and in relation to mortality.

Read the detailed description

Introduction A sudden and prolonged decline in renal function is defined as acute kidney injury (AKI). (1) Frequency of acute kidney injury is ranged from 30% to 67% of critically ill patient.(2,3). Nowadays the main marker used for diagnosis of AKI is serum creatinine which is functional marker, the change in its serum level may be delayed that delay diagnosis and management and may worsen outcome.(4) Within 1-4 hours following ischemic renal insult, NGAL has been shown to be detectable in the serum and urine, but until nowadays it has no clinical usage.(5, 6).

Patients and methods:

This single-center prospective non-randomized observational research has been performed on 120 cases, admitted to the critical care unit of the Sohag University Hospital between April 2020 and June 2022. A written and informed agreement was obtained from each patient or his first-degree guardian after clearance by the Sohag Faculty of Medicine's Ethics and Research Committee under IRB Registration Number: Soh-Med-23-01-31.

Inclusion criteria: All severely sick ICU patients older than 18 years old were included in the study.

Exclusion criteria: Patients with known chronic renal disease, those receiving hemodialysis, those with transplanted kidney, those with known kidney cancer, and patients who were just released from the ICU.

Methods: All included patients were subjected to the following: History taking, demographic data (age and gender), full medical history including co-morbid conditions (Chronic liver illness, ischemic heart disease, hypertension, and diabetes mellitus), medications, smoking status, previous surgeries, duration of hospital stay before ICU admission and infections including pneumonia, urinary tract infection, gastrointestinal tract, blood stream related infections or any wound infection. Complete clinical examination including BP, heart rate and O2 saturation, Glasgow coma scale (GCS), mean arterial pressure (MAP), temperature, respiration rate, oxygen saturation, presence or lack of lower limb edema, ascites and bed sores and measurement of urine output immediately on admission and every 6 hour. NGAL was measured utilizing an enzyme-linked immunosorbent assay (ELISA) sandwich method utilizing reagents from BT LAB. Symbol: E1719Hu. Size: 96T. Serum level of creatinine was measured immediately on admission and every 24 hours. Routine Laboratory investigations: Renal and liver functions, complete blood count and serum K, Na, PH, PCO2, PO2 and HCO3. Also, abdominal ultrasound comment on kidney echogenicity was performed. Utilizing the RIFLE-SCr method developed by the Acute Dialysis Quality Initiative (ADQI) group (7), participants were split into two groups: group A that advanced acute kidney injury or failure during their intensive care unit stay, and group B that didn't. Patients with AKI should consider dialysis if they have any of the following conditions: volume expansion that is resistant to diuretics, hyperkalemia resistant to medical treatment, severe acid-base disturbances resistant to medical treatment, severe azotemia (BUN >80-100), and uremia.

Primary outcome measure was the capability of serum NGAL levels to identify renal damage early in all patients requiring critical care. Secondary outcome measures were detection of patient outcome either; the need to RRT or patient mortality.

Sample size calculation Sample size was calculated using Power Analysis and Sample Size software program (PASS) version 15.0.5 for windows (2017) using data published by D. Youssef et al (2013) with the ability of NGAL to early detect renal injury in all critical care patients as the primary outcome. The null hypothesis was considered as the inability of NGAL to detect renal injury in all critical care patients. Youssef et. al (8) reported the area under the ROC curve of NGAL to early detection of AKI to be 0.63 with 95% confidence interval 0.50- 0.77.

Statistical analysis: Using IBM's SPSS statistics (Statistical Package for the Social Sciences) for Windows, the collected data were statistically examined (version 26). In order to ascertain if the data distribution was normal, the Shapiro-Wilk test was used. Regularly distributed continuous variables were stated as mean SD whereas categorical data and continuously distributed variables with aberrant distribution were given as median and interquartile range or number and percentage (as appropriate). The Student t test and Mann-Whitney tests were used, respectively, for continuous data with a normal distribution and those with an abnormal distribution. The chi square test was used to evaluate categorical data using the crosstabs function. There was a 95% confidence interval used for each test.

Being tested
Serum NGAL level
Keywords
Critically ill, neutrophil gelatinase-associated lipocalin, acute kidney injury.
Medical subject headings
Critical Illness, Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Serum NGAL levelOther

    serum NGAL level

Study groups in NCT06691607
Study groupRoleWhat they receive
Group AGroup A progressed to AKI
Receives: Other: Serum NGAL level
Group BGroup B did not progress to AKI
Receives: Other: Serum NGAL level

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. the capability of serum NGAL levels to identify renal damage early in all patients requiring critical care

    the capability of serum NGAL levels to identify renal damage early in all patients requiring critical care

    Measured: through study completion, an average of 1 year

Secondary outcomes (1)
  1. detection of patient outcome either; the need to RRT or patient mortality.

    detection of patient outcome either; the need to RRT or patient mortality.

    Measured: through study completion, an average of 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Nov 2024
  2. Study start1 Apr 2020
  3. Primary completion1 Mar 2022
  4. Study completion1 Jun 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
120 participants (actual)
Target duration
7 Days
IDs, dates and publications
ClinicalTrials.gov ID
NCT06691607
Sponsor's protocol ID
Soh-Med-23-01-31
Acronym
NGAL AKI
Status last verified
Nov 2024
First submitted
11 Nov 2024
Last updated
15 Nov 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: no plan to participate indevidual data

Questions about this trial

What is this clinical trial studying?

An observational study of To Determine If Blood Level (NGAL) Could Accurately Early Detect Acute Renal Damage in All Patients Requiring Critical Care, run by Sohag University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

the capability of serum NGAL levels to identify renal damage early in all patients requiring critical care (time frame: through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in